IFNG and neoplasm: In the setting of active immunotherapy patients have been vaccinated with “undefined” tumor specificities using autologous or allogeneic tumor cells whose immunogenicity has been enhanced by transfection of immune stimulatory molecules [11–13], IFNγ treatment [14] or by loading their lysate / fusing them with dendritic cells (DC) [15–17].